Related Experiment Videos
Serotonergic agonists behave as partial agonists at the dopamine D2 receptor
A Rinken1, S Ferré, A Terasmaa
1Institute of Chemical Physics, University of Tartu, Estonia.
Neuroreport
|April 20, 1999
Summary
Serotonergic agonists act as partial agonists at dopamine D2 receptors. This finding suggests potential therapeutic applications for Parkinson's disease treatments.
Area of Science:
- Neuropharmacology
- Receptor Binding Assays
Background:
- Dopamine D2 receptors play a crucial role in motor control.
- Understanding receptor interactions is key to developing effective Parkinson's disease therapies.
Purpose of the Study:
- To characterize the interaction of serotonergic agents with rat dopamine D2short receptors.
- To investigate the potential of these interactions for antiparkinsonian activity.
Main Methods:
- Utilized [35S]GTPgammaS binding assays to measure receptor activation.
- Employed dopaminergic agonists and antagonists, including (+)butaclamol.
- Conducted competition binding assays with [3H]raclopride.
Main Results:
- Serotonergic agonists (5-HT, 8OH-DPAT, 5-methoxytryptamine) demonstrated partial agonist activity at D2 receptors.
- Dopaminergic antagonist (+)butaclamol inhibited ligand activation with equal potency.
- Serotonergic agonists occupied fewer high-affinity binding sites compared to dopaminergic agonists.
Conclusions:
- Serotonergic agonists function as partial agonists at dopamine D2 receptors.
- These findings support the potential utility of serotonergic agents in managing Parkinson's disease.